. Author manuscript; available in PMC: 2011 Oct 1.

Published in final edited form as: Qual Saf Health Care. 2010 Aug 19;19(5):1–5. doi: 10.1136/qshc.2009.033050

Table 3.

Complications of ADEs caused by medication discrepancies, stratified by VA / non-VA group.

			Example:
ADE caused:	VA	Non-VA^*	Discrepancy (ADE)
No symptoms (%)	42	48	VA: Phenytoin dosage increase (supratherapeutic phenytoin level) Non-VA: Clonidine omitted (hypertension)
Symptoms only (%)	54	50	VA: Fentanyl transdermal omitted (pain) Non-VA: Carbamazepine dosage decrease (seizure and lethargy)
Prolonged or additional hospital stay (%)	4	2	VA: Nitroglycerin transdermal omitted (cardiac ischemia, hospital readmission) Non-VA: Colchicine omitted (gout flare, prolonged hospital stay)
Permanent harm or death (%)	0	0	None

P ≥ .05 for all comparisons with VA group, by chi-square test.